CytoMed Therapeutics Limited, a Singapore-based biopharmaceutical company, has entered into an At-the-Market Sales Agreement with R.F. Lafferty & Co., Inc. to offer and sell ordinary shares valued up to U.S.$4,304,945. The proceeds from this program will be used for general corporate purposes, business diversification, and potential acquisitions or strategic investments. The company’s cord blood bank acquisition has led to 2,500 new customer sign-ups contributing to revenue in 2025. CytoMed focuses on developing novel cell-based immunotherapies for various cancers using proprietary technologies. For more information, visit www.cytomed.sg.

This press release contains forward-looking statements regarding the company’s plans, development, and commercialization of product candidates. Investors are cautioned about potential risks and uncertainties that may impact actual results. Additional information can be found in the company’s filings with the SEC at www.sec.gov. For any inquiries, contact CytoMed Therapeutics Limited at [email protected].

Read more at GlobeNewswire: CytoMed Therapeutics Limited Announces At-the-Market (ATM)